Abstract
Primary aldosteronism has been recognized as a common cause of secondary hypertension, accounting for approximately 10% of the hypertensive population. Screening should be applied in hypertensive patients presenting with one of the following: hypokalemia, refractory hypertension, suggestive family history, or an incidentally detected adrenal mass. The most advocated screening test at present is the aldosterone-to-renin ratio, which has a high sensitivity but low specificity. The specificity increases if patients with low aldosterone concentrations are excluded. Published cut-off values vary depending on the hormone assay and the investigated population. Before screening, antihypertensive treatment, especially aldosterone antagonists and β-blockers, should be discontinued. A pathologic result requires additional work up to prove mineralocorticoid excess. Subtype differentiation is performed by adrenal venous sampling combined with imaging (CT or MRI). One-third of cases are due to aldosterone-producing adenomas, for which the preferred treatment is laparoscopic adrenalectomy. Bilateral adrenal hyperplasia (idiopathic aldosteronism) underlies two-thirds of cases and requires treatment with aldosterone antagonists. Treatment is started with low doses of spironolactone (25–50 mg once daily), which often results in substantial improvements in hypertension.
Key Points
-
Primary aldosteronism most frequently presents as normokalemic hypertension
-
In suspected cases, screening involves the aldosterone-to-renin ratio
-
Confirmatory testing (e.g. the saline suppression test) should follow a pathologic screening test result
-
After a confirmed diagnosis, patients undergo MRI or CT scan followed by adrenal venous sampling
-
Therapy consists of spironolactone treatment (25–100 mg) in patients with bilateral adrenal hyperplasia and unilateral adrenalectomy in those with aldosterone-producing adenomas
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vantyghem M et al. (1999) Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 141: 279–285
Benchetrit S et al. (2002) Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J 4: 17–20
Rayner B et al. (2000) The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 90: 394–400
Brown M et al. (1996) Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'? Aust N Z J Med 4: 533–538
Reincke M et al. (2003) Normokalemic primary aldosteronism [in German]. Dtsch Ärztebl 100: A184–A190
Bernini G et al. (2002) Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 146: 523–529
Fardella C et al. (2000) Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863–1867
Lim P et al. (1999) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353: 40
Gordon R et al. (1993) Evidence that primary aldosteronism may not be uncommon—twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20: 296–298
Seiler L et al. (2002) Prevalence of primary hyperaldosteronism in a university hypertension outpatient clinic: is it underdiagnosed? Exp Clin Endocrinol Diabetes 110: S84
Lim P et al. (2000) High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14: 311–315
Loh K et al. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85: 2854–2859
Rossi E et al. (2002) High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15: 896–902
Mulatero P et al. (2004) Increased diagnosis of primary aldosteronism including surgically correctable forms in centers from five continents. J Clin Endocrinol Metab 89: 1045–1050
Seiler L et al. (2004) Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150: 329–337
Williams J et al. (2006) Prevalence of primary aldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 20: 129–136
Kaplan N (2001) Cautions over the current epidemic of primary aldosteronism. Lancet 357: 953–954
Conn J and Lawrence H (1956) Primary aldosteronism, a new clinical entity. Ann Intern Med 44: 1–15
Rossi GP et al. (1996) Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27: 1039–1045
Mosso L et al. (2003) Primary aldosteronism and hypertensive disease. Hypertension 42: 161–165
Mulatero P et al. (2004) Genetics of primary aldosteronism. J Hypertens 22: 663–670
Fallo F et al. (1998) Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas. Exp Clin Endocrinol Diabetes 106: 74–78
Fontes R et al. (1991) Reassessment of the predictive value of the postural stimulation test in primary aldosteronism. Am J Hypertens 4: 786–791
Irony I et al. (1990) Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 3: 576–582
Connell J and Fraser R (2002) Primary aldosteronism. In The Oxford Textbook of Endocrinology and Diabetes, 791–799 (Eds Wass J and Shalet S) Oxford: Oxford University Press
Mulatero P et al. (2005) Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metabol 16: 114–119
Gordon R et al. (1995) Primary aldosteronism—some genetic, morphological, and biochemical aspects of subtypes. Steroids 60: 35–41
Ballantine DM et al. (1994) Renin gene polymorphism associated with aldosterone responsiveness to the renin–angiotensin system in patients with aldosterone-producing adenomas. Clin Exp Pharmacol Physiol 21: 215–218
Jackson R et al. (2002) New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 970: 77–88
Stewart P (2000) Dexamethasone-suppressible hypertension. Lancet 256: 679–699
Lifton R et al. (1992) A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262–265
Freel E et al. (2004) Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab 89: 2628–2633
Litchfield W et al. (1998) Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31: 445–450
McMahon G and Dluhy R (2004) Glucocorticoid-remediable aldosteronism. Cardiol Rev 12: 44–48
Stowasser M and Gordon R (2001) Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78: 215–229
Stowasser M and Gordon R (2000) Primary aldosteronism: learning from the study of familial varieties. J Hypertens 18: 1165–1176
Wambach G et al. (1986) Sodium loading raises urinary cortisol in man. J Endocrinol Invest 9: 257–259
Hiramatsu K et al. (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 141: 1589–1593
McKenna T et al. (1991) Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. J Clin Endocrinol Metab 73: 952–957
Schwartz G and Turner S (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51: 386–394
Giacchetti G et al. (2006) Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24: 737–745
Montori V et al. (2001) Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 76: 877–882
Padfield P (2003) Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol 59: 422–426
Auchus R (2003) Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr Opin Nephrol Hypertens 12: 153–158
Seifarth C et al. (2002) Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 57: 457–465
Gallay B et al. (2001) Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37: 699–705
Ferrari P et al. (2004) Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 22: 377–381
Trenkel S et al. (2002) Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 110: 80–85
Perschel F et al. (2004) Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 50: 1650–1655
Stowasser M et al. (2001) Diagnosis and management of primary aldosteronism. JRAAS 2: 156–169
Kem D et al. (1971) Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 128: 380–386
Mulatero P et al. (2006) Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrin Metab 91: 2618–2623
Schirpenbach C et al. (2006) Automated chemiluminescence immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 52: 1749–1755
Gordon R et al. (1999) A prospective evaluation of definite tests for primary aldosteronism. Abstracts from the Annual Scientific Meeting of the High Blood Pressure Research Council of Australia: 1999 December; Melbourne, Australia. Melbourne: HBP Research Council of Australia>
Schirpenbach C et al. (2006) Confirmatory testing in normokalaemic primary aldosteronism: the value of saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 154: 865–873
Agharazii M et al. (2001) Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37: 1440–1443
Young W (2002) Primary aldosteronism. Ann N Y Acad Sci 970: 61–76
Mantero F et al. (2003) Does dynamic testing have a place in the modern assessment of endocrine hypertension? J Endocrinol Invest 26: 92–98
Abdelhamid S et al. (2003) Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens 16: 522–530
Holland OB et al. (1984) Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 6: 717–723
Litchfield W et al. (1997) Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82: 3570–3573
Lingam R et al. (2003) CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. AJR Am J Roentgenol 181: 843–849
Guest P (2002) Adrenal imaging. In The Oxford Textbook of Endocrinology and Diabetes, 747–756 (Eds Wass J and Shalet S) Oxford: Oxford University Press
Lingam R et al. (2004) Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn's syndrome). Eur Radiol 14: 1787–1792
Young W et al. (2004) Role for adrenal venous sampling in primary aldosteronism. Surgery 136: 1227–1235
Rossi G et al. (2001) Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86: 1083–1090
Weinberger MH et al. (1979) Primary aldosteronism. Diagnosis, localization, and treatment. Ann Intern Med 90: 386–395
Doppman J and Gill J (1996) Hyperaldosteronism: sampling the adrenal veins. Radiology 198: 309–312
Sheaves R et al. (1996) Relative value of computed tomography scanning and venous sampling in establishing the cause of primary aldosteronism. Eur J Endocrinol 134: 308–313
Phillips J et al. (2000) Predictive value of preoperative tests in discriminating bilateral hyperplasia from an aldosterone-producing adenoma. J Clin Endocrinol Metab 85: 4526–4533
Wheeler M and Harris D (2003) Diagnosis and management of primary aldosteronism. World J Surg 27: 627–631
Lim P et al. (2001) A review of the medical treatment of primary aldosteronism. J Hypertens 19: 353–361
Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717
Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321
Epstein M (2003) Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 18: 1984–1992
Lumachi F et al. (2005) Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 71: 864–869
Lo C et al. (1996) Primary aldosteronism. Results of surgical treatment. Ann Surg 224: 125–130
Meyer A et al. (2005) Long-term follow-up after adrenalectomy for primary aldosteronsim. World J Surg 29: 155–159
Luton JP et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195–1201
Anonymous (1979) Idiopathic aldosteronism—a diagnostic artifact? Lancet 2(8154): 1221–1222
Kaplan NM (2004) The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 22: 863–869
Acknowledgements
The authors are grateful to Kathy Muller-Schertler for language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Schirpenbach, C., Reincke, M. Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nat Rev Endocrinol 3, 220–227 (2007). https://doi.org/10.1038/ncpendmet0430
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0430
This article is cited by
-
Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy
Scientific Reports (2021)
-
Imaging features of adrenal masses
Insights into Imaging (2019)
-
Was verursacht primären Hyperaldosteronismus?
CardioVasc (2019)